Key information

🔎 Fund Overview

Entrada Therapeutics, Inc. (Entrada) is a biopharmaceutical company aiming to transform the lives of patients by establishing a set of medicines, Endosomal Escape Vehicles (EEV) therapeutics, to engage intracellular targets that are considered inaccessible and undruggable. The Company's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, immunological, ocular, and metabolic diseases, among others. The Company’s lead oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44 and 45 skipping amenable, respectively, as well as its partnered candidate ENTR-701 targeting myotonic dystrophy type 1 (DM1).